Cerus Corporation and Swiss Red Cross Celebrate 10 Years of Routine Use of the INTERCEPT Blood System for Platelets | National company

CONCORD, Calif .– (BUSINESS WIRE) – July 14, 2021–

Cerus Corporation (Nasdaq: CERS), a company exclusively dedicated to safeguarding the global blood supply, and the Transfusion Service of the Swiss Red Cross (Blutspende SRK Schweiz) today announced the tenth anniversary of the use of the INTERCEPT blood system for all of its platelets supplied in Switzerland.

“We are honored to mark the tenth anniversary of the systematic use of INTERCEPT pads with our long-standing partners at the Swiss Red Cross,” said William ‘Obi’ Greenman, President and CEO of Cerus Corporation. “The transfusion medicine community in Switzerland has long been vigilant about blood safety and was among the first to adopt our technology on a large scale. The Swiss Red Cross recognized early on the value of implementing a proactive and “always active” approach to increasing the security of the country’s platelet supply. In this era of pandemic preparedness, we look forward to supporting their pioneering vision for safe and available blood. “

Since the Swiss Red Cross implemented the INTERCEPT blood system for platelets, Cerus has supplied INTERCEPT platelet kits for approximately 400,000 units of transfusable platelets in Switzerland with no reports of transfusion-transmitted infections, cases post-transfusion sepsis, death or other long-term side effect. observed effects. In addition, haemovigilance data for the routine use of INTERCEPT platelets in Switzerland have shown no increase in the use of platelets to treat patients.

“Cerus and the INTERCEPT platform have been critical contributors to our success in ensuring the security and availability of the supply of platelets in Switzerland over the past decade. The ability of the INTERCEPT system to inactivate bacteria has allowed us to transfuse patients with complete peace of mind without the risk of contamination, ”said Bernhard Wegmüller, President and CEO of the Transfusion Service of the Swiss Red Cross. “With emerging pathogens now fully recognized as a continuing reality in medicine, we are further assured by the additional layer of safety this technology offers to our patients receiving platelet transfusions,” continued Wegmüller.

“As the FDA compliance deadline for bacterial platelet contamination arrives in the United States, the experiences of blood centers that have pioneered the use of our pathogen inactivation technology, such as the Swiss Red Cross, have accumulated considerable experience with INTERCEPT blood. System that supports its continued adoption globally. Active haemovigilance data spanning many years of routine use by SRK and others underscores the usefulness and reliability of the INTERCEPT blood system in protecting the global blood supply, ”added Mr. Greenman.

ABOUT CERUS

Cerus Corporation is solely dedicated to safeguarding the blood supply in the world and aims to become the world’s leading blood products company. Headquartered in Concord, Calif., The company develops and supplies life-saving technologies and pathogen-protected blood components to blood centers, hospitals and ultimately to patients who depend on safe blood. The INTERCEPT Blood System for Platelets and Plasma is available worldwide and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe and in advanced clinical development in the United States. Also in the United States, INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive bleeding, associated with fibrinogen deficiency. For more information on Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and INTERCEPT Blood System are registered trademarks of Cerus Corporation.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210714005301/en/

CONTACT: Matt Notarianni – Senior Director, Investor Relations

Cerus Company

925-288-6137

KEYWORD: EUROPE SWITZERLAND UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: FDA MEDICAL DEVICES INFECTIOUS DISEASES HEALTH MEDICAL SUPPLIES

SOURCE: Cerus Corporation

Copyright Business Wire 2021.

PUB: 07/14/21 08:30 / DISC: 07/14/21 08:32

http://www.businesswire.com/news/home/20210714005301/en

Copyright Business Wire 2021.

About John Tuttle

Check Also

EPA: Chemicals in medical device cleaners pose cancer risk

WASHINGTON– The Environmental Protection Agency is warning residents who live near medical sterilization plants in …

Leave a Reply

Your email address will not be published.